Skip to main content
SpringerLink
Log in

Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?

  • Research Letter
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rice DP. Estimating the cost of illness. Am J Public Health. 1967;57:424–40.

    Article  CAS  Google Scholar 

  2. Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. Pharmacoeconomics. 2006;24:869–90.

    Article  PubMed  Google Scholar 

  3. Onukwugha E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Cost-of-illness studies: an updated review of current methods. Pharmacoeconomics. 2015;34:43–58.

    Article  Google Scholar 

  4. Clabaugh G, Ward M. Cost-of-illness in United States: a systematic review of methodologies for direct cost. Value Health. 2008;11:13–21.

    Article  PubMed  Google Scholar 

  5. Bloom BS, Bruno DJ, Maman DY, Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics. 2001;19:207–13.

    Article  CAS  PubMed  Google Scholar 

  6. Bloom BS, de Pouvourville N, Straus WL. Cost of illness of Alzheimer’s disease: how useful are current estimates? Gerontologist. 2003;43:158–64.

    Article  PubMed  Google Scholar 

  7. Mauskopf J, Mucha L. A review of the methods used to estimate the cost of Alzheimer’s disease in the United States. Am J Alzheimers Dis Other Demen. [Internet]. 2011;26:298–309. Available from: http://aja.sagepub.com/content/26/4/298.abstract.

  8. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479–500.

    Article  CAS  PubMed  Google Scholar 

  9. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology [Internet]. Bristol-Myers Squibb, Wallingford, CT, USA: Wiley; 2010;52:436–42. Available from: http://survey.hshsl.umaryland.edu/?url= http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=20683943&site=eds-live.

  10. Rein DB, Borton J, Liffmann DK, Wittenborn JS. The burden of hepatitis C to the United States Medicare system in 2009: descriptive and economic characteristics. Hepatology [Internet]. 2015;1–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26707033.

  11. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17:531–46.

    PubMed  Google Scholar 

  12. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis [Internet]. 2015;61:157–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25778747.

  13. Younossi ZM, Brown A, Buti M, Faiguoli S, Mauss S, Rosenberg W, et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat. 2016;23:217-226.

    Article  CAS  PubMed  Google Scholar 

  14. Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med. 2015;94118:1–9.

    Google Scholar 

  15. Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ. 2000;320:1335.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kymes S. “Can we declare victory and move on?” The case against funding burden-of-disease studies. Pharmacoeconomics. 2014;32:1153–5.

    Article  PubMed  Google Scholar 

  17. Donaldson C, Venkat Nararyan K. The cost of diabetes: a useful statistic? Diabetes Care. 1998;21:1370–1.

    Article  CAS  PubMed  Google Scholar 

  18. Currie G, Kerfoot KD, Donaldson C, Macarthur C. Are cost of injury studies useful? Inj. Prev. 2000;6:175–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6:177–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Koopmanschap MA. Cost-of-illness studies: useful for health policy? Pharmacoeconomics. 1998;14:143–8.

    Article  CAS  PubMed  Google Scholar 

  21. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy (New York). 2006;77:51–63.

    Article  Google Scholar 

  22. Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29:653–71.

    Article  PubMed  Google Scholar 

  23. Garfield E. The history and meaning of the journal impact factor. JAMA. 2006;295:90–3.

    Article  CAS  PubMed  Google Scholar 

  24. Kulkarni AV, Busse JW, Shams I. Characteristics associated with citation rate of the medical literature. PLoS One. 2007;2:1–5.

    Article  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Jacquelyn McRae, Alex Kravetz, Stefan Varga, and Rahul Khairnar for their work and contributions to developing the initial COI database of published studies from 2005 to 2014 and Kimberly Yang for her assistance in retrieving journal-specific information.

Author information

Authors and Affiliations

  1. University of Maryland School of Pharmacy, 20 North Pine Street, N415, Baltimore, MD, 21201, USA

    T. Joseph Mattingly II, C. Daniel Mullins & Eberechukwu Onukwugha

Authors
  1. T. Joseph Mattingly II
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Daniel Mullins
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eberechukwu Onukwugha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Joseph Mattingly II.

Ethics declarations

Author contributions and conflicts of interest

T Joseph Mattingly II collected and analyzed data, drafted the initial manuscript, and has no conflicts of interest. C. Daniel Mullins was primary research mentor to TJM, reviewed each draft of the manuscript, provided substantial input on revisions, and has no conflicts of interest. Eberechukwu Onukwugha was secondary research mentor to TJM, was responsible for the original database of COI studies, reviewed each draft of the manuscript, provided substantial input on revisions, and received no funding for this manuscript. Dr. Onukwugha declares grant funding from Bayer Healthcare and Takeda, as well as consulting fees from Astra Zeneca.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mattingly, T.J., Mullins, C.D. & Onukwugha, E. Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?. PharmacoEconomics 34, 1067–1070 (2016). https://doi.org/10.1007/s40273-016-0438-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-016-0438-4

Keywords

Search

Navigation